RNA: new CGT workstream to focus on this industry priority

newsSep 20, 2021 | Phorum : Cell & Gene Therapy | News

biophorum post images website graphics cgt september special4 158

When planning the 2021 BioPhorum Cell & Gene Therapy program, senior member representatives indicated that they wanted a new workstream focusing on what they considered to be the most critical topic: RNA. 

By early February 2021, companies were recruited to a pathfinder activity to determine what should be covered in the workstream: RNA – mRNA therapeutics and RNA tool. Discussions led to the creation of a charter, which has been reviewed by the new RNA workstream governance group consisting of 44 members from 20 companies.   

From the initial 16 topics identified, four have been confirmed for further scoping by dedicated sub-teams: 

  • RNA-specific CQA & CPP and links to clinical performance ​ 
  • Scale up challenges for RNA DS manufacturing and RNA DP ​ 
  • RNA-specific assays and analytical tools/equipment ​ 
  • CDMOs & CROs supporting RNA activity 

In addition to establishing this new workstream, BioPhorum has been working with members to produce an article on the importance of RNA within the biomanufacturing sector, containing more information about the pathfinder and its goals. The article will be published on BioPhorum.com before the end of the year. 

If you are interested in joining discussions on this critical topic, please contact steven.wall@biophorum.com or louise.bennett@biophorum.com 

Follow BioPhorum

Related tags

Recent releases

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Share This